Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Evaluation of -1498 c/t VEGF Polymorphism in the Prediction of Benefit From First-line Folfiri Plus Bevacizumab in Metastatic Colorectal Cancer Patients

NCT01363739 is registered in ClinicalTrials.gov with Azienda Ospedaliero, Universitaria Pisana as lead sponsor.

NCT NCT01363739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01363739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Evaluation of -1498 c/t VEGF Polymorphism in the Prediction of Benefit From First-line Folfiri Plus Bevacizumab in Metastatic Colorectal Cancer Patients
Lead sponsor
Azienda Ospedaliero, Universitaria Pisana
Phase
Observational
Overall status
Unknown status
Start date
April 30, 2009
Completion date
Not reported
Enrollment
265 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer